The Australian rifampicin trial.
D000328:Adult; D000368:Aged; D003365:Costs and Cost Analysis; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009164:Mycobacterium Infections / Q000188:drug therapy*; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use*; D013183:Sputum / Q000382:microbiology; D014376:Tuberculosis / Q000188:drug therapy; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000382:microbiology
D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin